Better Therapeutics (NASDAQ:BTTX) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS

Better Therapeutics (NASDAQ:BTTX – Get Rating) posted its quarterly earnings data on Friday. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.11), MarketWatch Earnings reports.

NASDAQ BTTX traded down $0.09 during trading hours on Friday, reaching $1.74. 1,163,913 shares of the company were exchanged, compared to its average volume of 16,973,454. Better Therapeutics has a 1 year low of $0.91 and a 1 year high of $29.40. The firm has a 50 day simple moving average of $2.02. The company has a debt-to-equity ratio of 0.26, a quick ratio of 9.56 and a current ratio of 9.56.

In related news, Director Andrew J. Armanino acquired 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 29th. The stock was acquired at an average price of $2.14 per share, for a total transaction of $85,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have purchased 47,500 shares of company stock valued at $100,425 in the last 90 days.

Large investors have recently modified their holdings of the business. State Street Corp bought a new position in Better Therapeutics during the fourth quarter worth about $62,000. Northern Trust Corp bought a new position in Better Therapeutics during the fourth quarter worth about $78,000. D. E. Shaw & Co. Inc. bought a new position in Better Therapeutics during the fourth quarter worth about $148,000. Millennium Management LLC bought a new position in Better Therapeutics during the fourth quarter worth about $318,000. Finally, Vanguard Group Inc. boosted its position in Better Therapeutics by 39.6% during the first quarter. Vanguard Group Inc. now owns 284,395 shares of the company’s stock worth $563,000 after purchasing an additional 80,633 shares during the period. Hedge funds and other institutional investors own 14.97% of the company’s stock.

Separately, Chardan Capital raised their price objective on shares of Better Therapeutics from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, March 16th.

Better Therapeutics Company Profile (Get Rating)

Better Therapeutics, Inc engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes.

Recommended Stories